227 related articles for article (PubMed ID: 38106883)
1. Successful treatment of nivolumab and ipilimumab triggered type 1 diabetes by using sodium-glucose transporter 2 inhibitor: a case report and systematic review.
Fujiwara M; Shimizu M; Okano T; Maejima Y; Shimomura K
Front Public Health; 2023; 11():1264056. PubMed ID: 38106883
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
[TBL] [Abstract][Full Text] [Related]
3. [Diabetic euglycemic ketosis or ketoacidosis in individuals with type 2 diabetes treated by SGLT2 inhibitors: A series of Belgian clinical cases].
Menghoum N; Oriot P; Hermans MP; Mariage JL
Rev Med Interne; 2020 Apr; 41(4):226-231. PubMed ID: 31866073
[TBL] [Abstract][Full Text] [Related]
4. Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma.
Changizzadeh PN; Mukkamalla SKR; Armenio VA
J Immunother Cancer; 2017 Dec; 5(1):97. PubMed ID: 29254501
[TBL] [Abstract][Full Text] [Related]
5. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
Yaura K; Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2021 Aug; 254(4):253-256. PubMed ID: 34373422
[TBL] [Abstract][Full Text] [Related]
6. A Case Report of Diabetic Ketoacidosis With Combined Use of a Sodium Glucose Transporter 2 Inhibitor and Hybrid Closed-Loop Insulin Delivery.
Singh S; Rushakoff RJ; Neinstein AB
J Diabetes Sci Technol; 2019 May; 13(3):605-606. PubMed ID: 30931610
[No Abstract] [Full Text] [Related]
7. Rare, late onset of immune checkpoint inhibitor-induced type 1 diabetes mellitus in a patient with small-cell lung cancer treated with serplulimab: a case report and review of the literature.
Ning P; Liu S; Cao H
J Med Case Rep; 2024 Jan; 18(1):51. PubMed ID: 38247005
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic mucosal melanoma.
Goff CB; Plaxe SC; White W; Dasanu CA
J Oncol Pharm Pract; 2023 Jul; 29(5):1259-1263. PubMed ID: 36734125
[TBL] [Abstract][Full Text] [Related]
9. On-label use of sodium-glucose cotransporter 2 inhibitors might increase the risk of diabetic ketoacidosis in patients with type 1 diabetes.
Horii T; Oikawa Y; Atsuda K; Shimada A
J Diabetes Investig; 2021 Sep; 12(9):1586-1593. PubMed ID: 33448127
[TBL] [Abstract][Full Text] [Related]
10. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
Burke KR; Schumacher CA; Harpe SE
Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
[TBL] [Abstract][Full Text] [Related]
11. Dapagliflozin-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus: A case report.
Lee IH; Ahn DJ
Medicine (Baltimore); 2020 May; 99(21):e20228. PubMed ID: 32481295
[TBL] [Abstract][Full Text] [Related]
12. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
Musso G; Sircana A; Saba F; Cassader M; Gambino R
PLoS Med; 2020 Dec; 17(12):e1003461. PubMed ID: 33373368
[TBL] [Abstract][Full Text] [Related]
13. Diabetic Ketoacidosis as a Delayed Immune-Related Event after Discontinuation of Nivolumab.
Mae S; Kuriyama A; Tachibana H
J Emerg Med; 2021 Mar; 60(3):342-344. PubMed ID: 33097350
[TBL] [Abstract][Full Text] [Related]
14. New-onset type 1 diabetes mellitus as a delayed immune-related event after discontinuation of nivolumab: A case report.
Seo JH; Lim T; Ham A; Kim YA; Lee M
Medicine (Baltimore); 2022 Sep; 101(35):e30456. PubMed ID: 36107574
[TBL] [Abstract][Full Text] [Related]
15. Sodium-glucose cotransporter 2 inhibitor-induced euglycemic diabetic ketoacidosis in a patient with coronavirus disease 2019: a case report.
Yii ESS; Azli AW; Sitaram PN
J Med Case Rep; 2022 Jan; 16(1):17. PubMed ID: 34983625
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitor-induced takotsubo syndrome and diabetic ketoacidosis: rare reactions.
Oldfield K; Jayasinghe R; Niranjan S; Chadha S
BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33526518
[TBL] [Abstract][Full Text] [Related]
17. Beware Ketoacidosis with SGLT2 Inhibitors in Latent Autoimmune Diabetes of the Adult.
Nolan BJ; Varadarajan S; Fourlanos S; Neoh SL
Am J Med; 2020 Aug; 133(8):e422-e424. PubMed ID: 31923401
[TBL] [Abstract][Full Text] [Related]
18. An atypical hyperosmolar hyperglycemic state and diabetic ketoacidosis induced by sodium-glucose cotransporter-2 inhibitors: A case report.
Wang CT; Chang CW; Lu YC; Lam HC; Ku SJ; Tseng KB; Kao YH
J Formos Med Assoc; 2020 Aug; 119(8):1325-1328. PubMed ID: 31813656
[TBL] [Abstract][Full Text] [Related]
19. Fulminant ACTH decrease following diabetic ketoacidosis induced by immune checkpoint inhibitor combination therapy with nivolumab and ipilimumab: A case report.
Iesaka H; Kameda H; Miya A; Nomoto H; Cho KY; Nakamura A; Abe T; Shinohara N; Atsumi T
Medicine (Baltimore); 2023 Dec; 102(51):e36664. PubMed ID: 38134115
[TBL] [Abstract][Full Text] [Related]
20. Case Report: High-Calorie Glucose Infusion and Tight Glycemic Control in Ameliorating Refractory Acidosis of Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis.
Wan Azman SS; Sukor N; Abu Shamsi MY; Ismail I; Kamaruddin NA
Front Endocrinol (Lausanne); 2022; 13():867647. PubMed ID: 35712244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
